TriangleIvonescimab (NCT07516925)
Ivonescimab trial for Leiomyosarcoma (NCT07516925). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic leiomyosarcoma after one to three systemic treatment lines, or who decline standard first-line treatment. Prior PD-1/PD-L1 or VEGF inhibitors are excluded.
The idea: ivonescimab targets PD-1 to release immune brakes and VEGF to block blood-vessel growth. Patients receive it intravenously every three weeks for up to two years. Researchers measure tumor response and safety.
This phase 2 study plans 20 patients. Sandra D’Angelo leads at Memorial Sloan Kettering in New York. Seven US locations are marked recruiting; six permit only limited protocol activities.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.